Trillium Asset Management LLC Has $2.38 Million Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• Trillium Asset Management LLC increased its holdings in TransMedics Group by 7.4%, owning approximately 0.10% of the company valued at $2.38 million after purchasing additional shares.
• Several hedge funds, including Braidwell LP and UBS AM, have significantly boosted their stakes in TransMedics Group, contributing to institutional investors owning 99.67% of the company's stock.
• TransMedics Group reported a 37.7% increase in quarterly revenue year-over-year, surpassing analyst expectations with earnings of $0.92 per share against estimates of $0.48.

Trillium Asset Management LLC increased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,389 shares of the company's stock after purchasing an additional 2,442 shares during the period. Trillium Asset Management LLC owned approximately 0.10% of TransMedics Group worth $2,381,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. OneDigital Investment Advisors LLC increased its stake in TransMedics Group by 52.6% in the first quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company's stock valued at $403,000 after acquiring an additional 2,065 shares during the period. Principal Financial Group Inc. increased its stake in TransMedics Group by 2.8% in the first quarter. Principal Financial Group Inc. now owns 198,427 shares of the company's stock valued at $13,350,000 after acquiring an additional 5,480 shares during the period. Vontobel Holding Ltd. bought a new stake in TransMedics Group in the first quarter valued at about $291,000. New York State Teachers Retirement System increased its stake in TransMedics Group by 183.2% in the first quarter. New York State Teachers Retirement System now owns 21,949 shares of the company's stock valued at $1,477,000 after acquiring an additional 14,200 shares during the period. Finally, Sugar Maple Asset Management LLC bought a new stake in TransMedics Group in the first quarter valued at about $740,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TMDX shares. Morgan Stanley upped their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Oppenheimer upped their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, TransMedics Group presently has a consensus rating of "Moderate Buy" and a consensus price target of $123.00.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider directly owned 13,955 shares of the company's stock, valued at $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Basile sold 5,000 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the transaction, the director owned 2,866 shares in the company, valued at $362,405.70. This represents a 63.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,418 shares of company stock valued at $818,833 over the last three months. 7.00% of the stock is owned by insiders.

TransMedics Group Price Performance

Shares of TMDX traded down $2.30 during mid-day trading on Thursday, hitting $129.74. 875,947 shares of the company traded hands, compared to its average volume of 1,392,768. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The business has a 50-day moving average of $123.89 and a 200 day moving average of $99.05. The stock has a market capitalization of $4.42 billion, a price-to-earnings ratio of 67.22 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. During the same period in the prior year, the firm earned $0.35 earnings per share. TransMedics Group's revenue was up 37.7% compared to the same quarter last year. As a group, equities analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.